Abstract
Background: Statins have been proposed to reduce the risk of Alzheimer's disease (AD). Objective: Assess whether long-term statin use was associated with neuroimaging biomarkers of aging and dementia. Methods: We analyzed neuroimaging biomarkers in 1,160 individuals aged 65+ from the Mayo Clinic Study of Aging, a population-based prospective longitudinal study of cognitive aging. Results: Statin-treated (5+ years of therapy) individuals had greater burden of mid-and late-life cardiovascular disease (p < 0.001) than statin-untreated (=3 months) individuals. Lower fractional anisotropy in the genu of the corpus callosum, an early marker of cerebrovascular disease, was associated with long-term statin exposure (p < 0.035). No significant associations were identified between long-term statin exposure and cerebral amyloid or tau burden, AD pattern neurodegeneration, or white matter hyperintensity burden. Conclusion: Long-term statin therapy was not associated with differences in AD biomarkers. Individuals with long-term statin exposure had worse white matter integrity in the genu of the corpus callosum, consistent with the coexistence of higher cerebrovascular risk factor burden in this group.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1345-1352 |
| Number of pages | 8 |
| Journal | Journal of Alzheimer's Disease |
| Volume | 65 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jan 1 2018 |
Fingerprint
Keywords
- Alzheimer's disease
- amyloid
- biomarkers
- cerebrovascular disease
- magnetic resonance imaging
- neurodegeneration
- positron emission tomography
- statins
- tau
- white matter
ASJC Scopus subject areas
- Neuroscience(all)
- Clinical Psychology
- Geriatrics and Gerontology
- Psychiatry and Mental health
Cite this
Statins and Brain Health : Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults. / Ramanan, Vijay K.; Przybelski, Scott A.; Graff-Radford, Jonathan; Castillo, Anna M.; Lowe, Val; Mielke, Michelle M; Roberts, Rosebud O; Reid, Robert I.; Knopman, David S; Jack, Clifford R Jr.; Petersen, Ronald Carl; Vemuri, Prashanthi D.
In: Journal of Alzheimer's Disease, Vol. 65, No. 4, 01.01.2018, p. 1345-1352.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Statins and Brain Health
T2 - Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults
AU - Ramanan, Vijay K.
AU - Przybelski, Scott A.
AU - Graff-Radford, Jonathan
AU - Castillo, Anna M.
AU - Lowe, Val
AU - Mielke, Michelle M
AU - Roberts, Rosebud O
AU - Reid, Robert I.
AU - Knopman, David S
AU - Jack, Clifford R Jr.
AU - Petersen, Ronald Carl
AU - Vemuri, Prashanthi D
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Background: Statins have been proposed to reduce the risk of Alzheimer's disease (AD). Objective: Assess whether long-term statin use was associated with neuroimaging biomarkers of aging and dementia. Methods: We analyzed neuroimaging biomarkers in 1,160 individuals aged 65+ from the Mayo Clinic Study of Aging, a population-based prospective longitudinal study of cognitive aging. Results: Statin-treated (5+ years of therapy) individuals had greater burden of mid-and late-life cardiovascular disease (p < 0.001) than statin-untreated (=3 months) individuals. Lower fractional anisotropy in the genu of the corpus callosum, an early marker of cerebrovascular disease, was associated with long-term statin exposure (p < 0.035). No significant associations were identified between long-term statin exposure and cerebral amyloid or tau burden, AD pattern neurodegeneration, or white matter hyperintensity burden. Conclusion: Long-term statin therapy was not associated with differences in AD biomarkers. Individuals with long-term statin exposure had worse white matter integrity in the genu of the corpus callosum, consistent with the coexistence of higher cerebrovascular risk factor burden in this group.
AB - Background: Statins have been proposed to reduce the risk of Alzheimer's disease (AD). Objective: Assess whether long-term statin use was associated with neuroimaging biomarkers of aging and dementia. Methods: We analyzed neuroimaging biomarkers in 1,160 individuals aged 65+ from the Mayo Clinic Study of Aging, a population-based prospective longitudinal study of cognitive aging. Results: Statin-treated (5+ years of therapy) individuals had greater burden of mid-and late-life cardiovascular disease (p < 0.001) than statin-untreated (=3 months) individuals. Lower fractional anisotropy in the genu of the corpus callosum, an early marker of cerebrovascular disease, was associated with long-term statin exposure (p < 0.035). No significant associations were identified between long-term statin exposure and cerebral amyloid or tau burden, AD pattern neurodegeneration, or white matter hyperintensity burden. Conclusion: Long-term statin therapy was not associated with differences in AD biomarkers. Individuals with long-term statin exposure had worse white matter integrity in the genu of the corpus callosum, consistent with the coexistence of higher cerebrovascular risk factor burden in this group.
KW - Alzheimer's disease
KW - amyloid
KW - biomarkers
KW - cerebrovascular disease
KW - magnetic resonance imaging
KW - neurodegeneration
KW - positron emission tomography
KW - statins
KW - tau
KW - white matter
UR - http://www.scopus.com/inward/record.url?scp=85054132077&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054132077&partnerID=8YFLogxK
U2 - 10.3233/JAD-180446
DO - 10.3233/JAD-180446
M3 - Article
C2 - 30149450
AN - SCOPUS:85054132077
VL - 65
SP - 1345
EP - 1352
JO - Journal of Alzheimer's Disease
JF - Journal of Alzheimer's Disease
SN - 1387-2877
IS - 4
ER -